Sky,
If I am not mistaken, the success of the deal between $NWBO and Roswell depends on whether Roswell can have a successful p3 trial. Did I get that right?
The in-license technology is related to the one developed by Roswell to disrupt the growth of tumor blood vessel. If I am not mistaken, Roswell can pulse DCs with neo-peptides so that t cells can target HER2. It seems to me that the combination currently adopted in the combo trial doesn't need their technology. Can we see how tumor cells were significantly reduced within three weeks of the administration of DCVAX-L?
We do see that Roswell extended the completion date of the tumor agnostic trial by two years. If their technology were so outstanding and were able to shrink tumors in months, they wouldn't have extended the completion date. It strikes me that the in-license deal was meant mostly to boost the sp. The above is just my conjecture though.
Market Data 
Markets 
AI
